Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.31 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.31 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.31 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207927 | 0.84 | PARP1 (0.37) | CNR2PARP1MAPK14SMN1; SMN2MAPK13 | |
| SCHEMBL3206314 | 0.80 | YEATS4 (0.31) | YEATS4 | |
| SCHEMBL3241618 | 0.76 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5244557 | 0.75 | EPHX2 (0.31) | — | |
| SCHEMBL3545622 | 0.75 | CNR2 (0.34) | CNR2PARP1MAPK14SMN1; SMN2RAF1 | |
| SCHEMBL3549555 | 0.74 | MAPK14 (0.60) | MAPK14RAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL3546185 | 0.73 | MAPK14 (0.36) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3545113 | 0.73 | PARP1 (0.37) | CNR2PARP1SMN1; SMN2 | |
| SCHEMBL13495559 | 0.73 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3549028 | 0.73 | RAF1 (0.47) | MAPK14RAF1MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010019930-A1 | UREA DERIVATIVES AS INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | CNR2 4569/4885PARP1 2990/4885MAPK14 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.